Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants

Hepatitis C virus (HCV) is a global health burden affecting approximately 71 million people worldwide [1]. Infection often leads to chronic hepatitis, with the subsequent risk for liver cirrhosis and hepatocellular carcinoma. Persistent HCV infection is now curable with the introduction of direct-acting antivirals (DAAs). However, a prophylactic HCV vaccine is not available. Since viral re-infection is possible and as many HCV infected individuals are not diagnosed, a vaccine against HCV would facilitate global HCV eradication programs.

Source: Journal of Hepatology - November 12, 2018 Category: Gastroenterology Authors: Tanvi Khera, Patrick Behrendt, Dorothea Bankwitz, Richard J.P. Brown, Daniel Todt, Mandy Doepke, Abdul Ghafoor Khan, Kai Schulze, John Law, Michael Logan, Darren Hockman, Jason Alexander Ji-Xhin Wong, Leona Dold, Victor Gonzalez-Motos, Ulrich Spengler, Ab Source Type: research